Previous 10 | Next 10 |
3 Ways to Improve Your Chances of Profitability With Penny Stocks Having consistent gains when investing in penny stocks is critical due to the volatile nature of the stock market. The price of penny stocks can fluctuate rapidly and you may end up losing your investment if you are not car...
Top 3 Strategies to Use for Trading Penny Stocks Next Year Penny stocks are a popular but risky investment option due to their potential for high returns. Having a trading strategy with penny stocks is important in order to minimize the risk involved and maximize profits. A good trading strat...
- Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints - - DMT310 produced no serious adverse events related to treatment - - Dermata remains on track to request an End of Phase 2 meeting with the FDA for DMT310 for ...
A California-based %Biotech firm turned heads on Wednesday after the company announced that it filed a shelf registration statement for the potential sale of up to $100 million of its securities from time to time, according to the release. This sent shares of %DermataTherapeutics ($...
Dermata Therapeutics press release ( NASDAQ: DRMA ): Q3 GAAP EPS of -$0.20. As of September 30, 2022, Dermata had $8.1 million in cash and cash equivalents, compared to $10.8 million as of December 31, 2021. Dermata expects its current cash resources are sufficient to fund...
- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 - SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("D...
SAN DIEGO, CA / ACCESSWIRE / September 6, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Boar...
Dermata Therapeutics press release ( NASDAQ: DRMA ): Q2 GAAP EPS of -$0.24 (vs. -$0.70 Y/Y). As of Jun. 30, Dermata had $10.6M in cash. Shares -4.29% AH. For further details see: Dermata Therapeutics Q2 GAAP EPS of -$0.24
Dermata completes a $5.0 million private placement financing in April 2022 DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022 SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"),...
The definition of penny stocks includes stocks under $5, but for some, that’s too expensive. True penny stocks trading for less than $1 seem to have gained much more attention in the stock market today. Thanks partly to the overall stock market crash this year, many new stocks ar...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...